SS-31
A mitochondria-targeted peptide studied for cellular energy and tissue-protection questions.
Also referenced as: Elamipretide
Also appears in: Recovery
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Anti-Aging. Also surfaces under Recovery for browsing and discovery.
Elamipretide
FDA label signal · 31 trials · 426 PubMed results
What SS-31 is
SS-31 is a mitochondria-targeted peptide commonly referenced in energy, recovery, and aging-related research discussions. In development contexts it is often referred to as elamipretide.
Why it matters
It sits in the same broad mitochondrial-interest lane as MOTS-c and humanin, but with a more explicit investigational-development framing.
Regulatory context
SS-31 is not FDA approved in the United States. It is better classified here as investigational rather than as an approved therapy.
Practical reading note
Mitochondrial peptides often sound especially advanced in marketing copy, so it helps to distinguish mechanistic intrigue from actual clinical availability.